Literature DB >> 6481425

Complications associated with intra-arterial BCNU administered in combination with vincristine and procarbazine for the treatment of malignant brain tumors.

A M Bremer, E Kleriga, T Q Nguyen, R Balsys, H M Northup, N Gonzalez, P Duarte, R I Miller.   

Abstract

We have used intra-arterial (i.a.) 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) either alone or as part of adjuvant chemotherapy in patients with malignant brain tumors over a 3 year period (1979-1982). The i.a. BCNU technique was used 111 times to infuse 134 arteries in 37 patients. These patients, 28 cases with glial tumor and 9 cases with brain metastasis, received i.a. BCNU in combination with Vincristine and Procarbazine every 6 weeks. Complications encountered were transient and included: periorbital erythralgia or occipital-nuchal pain in 23 (62%), mild confusion and disorientation in 14 (38%), and ipsilateral conjunctival edema in 10 (27%). Reversible myelosuppression was not found. Our findings suggest that BCNU (100 mg/M2) may be given by i.a. infusion in combination chemotherapy without persistent severe untoward effects with a cumulative dose of 700 mg/M2.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6481425     DOI: 10.1007/bf00177898

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  CANCER CHEMOTHERAPY BY PROLONGED ARTERIAL INFUSION.

Authors:  E WATKINS; R D SULLIVAN
Journal:  Surg Gynecol Obstet       Date:  1964-01

2.  Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report.

Authors:  C T KLOPP; T C ALFORD; J BATEMAN; G N BERRY; T WINSHIP
Journal:  Ann Surg       Date:  1950-10       Impact factor: 12.969

3.  Effects of intracarotid administration of nitrogen mustard on normal brain and brain tumors.

Authors:  J D FRENCH; P M WEST; F K VON AMERONGEN; H W MAGOUN
Journal:  J Neurosurg       Date:  1952-07       Impact factor: 5.115

4.  Regional chemotherapeutic perfusion and infusion of brain and face tumors.

Authors:  M S Mahaley; B Woodhall
Journal:  Ann Surg       Date:  1967-08       Impact factor: 12.969

5.  New implantable continuous administration and bolus dose intracarotid drug delivery system for the treatment of malignant gliomas.

Authors:  T W Phillips; W F Chandler; G W Kindt; W D Ensminger; H S Greenberg; J F Seeger; K M Doan; J W Gyves
Journal:  Neurosurgery       Date:  1982-08       Impact factor: 4.654

6.  Supraophthalmic carotid infusion for brain-tumor chemotherapy. Technical note.

Authors:  J P Kapp; R L Ross; E M Tucker
Journal:  J Neurosurg       Date:  1983-04       Impact factor: 5.115

7.  Limitations of high dose intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy for malignant gliomas.

Authors:  J Kapp; R Vance; J L Parker; R R Smith
Journal:  Neurosurgery       Date:  1982-06       Impact factor: 4.654

8.  Intra-arterial BCNU therapy in the treatment of metastatic brain tumor from lung carcinoma: a preliminary report.

Authors:  K Yamada; A M Bremer; C R West; J Ghoorah; H C Park; H Takita
Journal:  Cancer       Date:  1979-12       Impact factor: 6.860

9.  Intra-arterial BCNU chemotherapy for the treatment of malignant gliomas of the central nervous system: a preliminary report.

Authors:  H S Greenberg; W D Ensminger; J F Seeger; G W Kindt; F Chandler; K Doan; S R Dakhil
Journal:  Cancer Treat Rep       Date:  1981 Sep-Oct

10.  Phase II study--intra-arterial BCNU therapy for metastatic brain tumors.

Authors:  S Madajewicz; C R West; H C Park; J Ghoorah; A M Avellanosa; H Takita; C Karakousis; R Vincent; J Caracandas; E Jennings
Journal:  Cancer       Date:  1981-02-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.